Evidence map›Paper›PMID 33288723›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

Mesyl phosphoramidate backbone modified antisense oligonucleotides targeting miR-21 with enhanced in vivo therapeutic potency.

Olga A Patutina, Svetlana K Gaponova Miroshnichenko, Aleksandra V Sen'kova, Innokenty A Savin, Daniil V Gladkikh, Ekaterine A Burakova, Alesya A Fokina, Mikhail A Maslov, Elena V Shmendel', Mattew J A Wood and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 73 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. RNA chemistry and therapeutics.Nature reviews. Drug discovery · 2025
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Unlocking Parkinson's disease: the role of microRNAs in regulation, diagnosis, and therapy.Apoptosis : an international journal on programmed cell death · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Olga A PatutinaLaboratory of Nucleic Acids Biochemistry, Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
Svetlana K Gaponova MiroshnichenkoLaboratory of Nucleic Acids Biochemistry, Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
Aleksandra V Sen'kovaLaboratory of Nucleic Acids Biochemistry, Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
Innokenty A SavinLaboratory of Nucleic Acids Biochemistry, Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
Daniil V GladkikhLaboratory of Nucleic Acids Biochemistry, Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
Ekaterine A BurakovaDepartment of Physics, Novosibirsk State University, 630090 Novosibirsk, Russia.
Alesya A FokinaDepartment of Physics, Novosibirsk State University, 630090 Novosibirsk, Russia.
Mikhail A MaslovDepartment of Chemistry and Technology of Biologically Active Compounds, Medical and Organic Chemistry Named after N. A. Preobrazhensky, Moscow Institute of Radio Engineering, Electronics and Automation-Russian Technological University, 119454 Moscow, Russia.ORCID 0000-0002-5372-1325
Elena V Shmendel'Department of Chemistry and Technology of Biologically Active Compounds, Medical and Organic Chemistry Named after N. A. Preobrazhensky, Moscow Institute of Radio Engineering, Electronics and Automation-Russian Technological University, 119454 Moscow, Russia.
Mattew J A WoodDepartment of Paediatrics, University of Oxford, OX3 9DU Oxford, United Kingdom.
Valentin V VlassovLaboratory of Nucleic Acids Biochemistry, Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia.
Sidney AltmanDepartment of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT 06520-8103; sidney.altman@yale.edu marzen@niboch.nsc.ru.ORCID 0000-0001-7287-0337
Dmitry A StetsenkoDepartment of Physics, Novosibirsk State University, 630090 Novosibirsk, Russia.
Marina A ZenkovaLaboratory of Nucleic Acids Biochemistry, Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 630090 Novosibirsk, Russia; sidney.altman@yale.edu marzen@niboch.nsc.ru.
Institute of Chemical Biology and Fundamental Medicine · RUNovosibirsk State University · RUMIREA - Russian Technological University · RUUniversity of Oxford · GBYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The design of modified oligonucleotides that combine in one molecule several therapeutically beneficial properties still poses a major challenge. Recently a new type of modified mesyl phosphoramidate (or µ-) oligonucleotide was described that demonstrates high affinity to RNA, exceptional nuclease resistance, efficient recruitment of RNase H, and potent inhibition of key carcinogenesis processes in vitro. Herein, using a xenograft mouse tumor model, it was demonstrated that microRNA miR-21-targeted µ-oligonucleotides administered in complex with folate-containing liposomes dramatically inhibit primary tumor growth via long-term down-regulation of miR-21 in tumors and increase in biosynthesis of miR-21-regulated tumor suppressor proteins. This antitumoral effect is superior to the effect of the corresponding phosphorothioate. Peritumoral administration of µ-oligonucleotide results in its rapid distribution and efficient accumulation in the tumor. Blood biochemistry and morphometric studies of internal organs revealed no pronounced toxicity of µ-oligonucleotides. This new oligonucleotide class provides a powerful tool for antisense technology.

Indexed as

AmidesAnimalsAntineoplastic AgentsCell Line, TumorGene Expression Regulation, NeoplasticMaleMelanomaMice, SCIDMicroRNAsMolecular Targeted TherapyOligonucleotides, AntisensePhosphoric AcidsTissue DistributionXenograft Model Antitumor AssaysAmidesAntineoplastic AgentsMicroRNAsMIRN21 microRNA, humanOligonucleotides, Antisensephosphoramidic acidPhosphoric Acidsantisense oligonucleotideDNA modificationmesyl oligonucleotideoncogenic microRNAphosphorothioate

Identifiers

PMID33288723
PMCPMC7768764
OpenAlexW3112127044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.